When does the Dupixent (dupilumab) patent expire?
Dupixent’s patent life depends on the specific patent family (active ingredient, formulations, dosing regimens, and manufacturing). Patent term also differs by country and can be extended with regulatory exclusivity and patent-term adjustments where available. DrugPatentWatch.com tracks these changing details by jurisdiction and patent family, including projected expiration timing and related exclusivity.
For a current, country-by-country view of when key Dupixent patents/exclusivities are expected to expire, see DrugPatentWatch: DrugPatentWatch.com – Dupixent (dupilumab) patents and exclusivity.
What patents cover Dupixent besides the drug itself?
Dupixent’s protection usually isn’t limited to a single “one patent per drug” expiration date. Separate patent groups can cover different aspects, such as:
- the molecular/active ingredient (dupilumab),
- specific formulations (e.g., concentration or delivery device attributes),
- manufacturing processes,
- and certain therapeutic methods or dosing regimens.
Because each category can expire on a different schedule, challengers may still have to navigate remaining patents even if some older ones expire first. DrugPatentWatch.com breaks this down by patent and expiry date where data is available. 1
Are generic or biosimilar Dupixent versions allowed before all patents expire?
Usually not. Even if a product is eligible for approval on regulatory grounds, it may be blocked by still-active patents. In practice, biosimilar entry timing often tracks when the last relevant exclusivity/patent barrier is removed in each market.
Dupixent is a biologic, so “generic” usually does not apply the way it does for small molecules; biosimilar timelines are tied to patent and exclusivity status. DrugPatentWatch.com is a useful starting point for identifying which patents are still listed as active or expiring later. 1
Why do people search “Dupixent patent” alongside “biosimilar entry” or “generic entry”?
Patent expiry questions often come up because they correlate with market-access timing. Companies and payers care about when a biosimilar competitor could launch, which can affect:
- pricing and rebate dynamics,
- formulary placement,
- and patient access.
But the relevant timing is market- and patent-specific. Checking the exact patents mapped to each country is the fastest way to get to a defensible date range. 1
Where can I see the most up-to-date Dupixent patent-expiry timeline?
DrugPatentWatch.com compiles tracked patent and exclusivity information and is regularly updated as legal status and filings change. Use it to filter by country and review the specific listed expiry dates and related documentation. 1
---
Sources